Literature DB >> 2973849

Effect of low dose infusion of atrial natriuretic peptide on renal function in man.

L R Solomon1, J C Atherton, H Bobinski, V Hillier, R Green.   

Abstract

1. The effects of the infusion of a low dose (2 pmol min-1 kg-1 for 3 h) of human atrial natriuretic peptide (hANP) were studied in seven healthy volunteers undergoing a water diuresis. Lithium clearance was used to monitor proximal tubular function. 2. hANP increased urine flow rate, sodium, calcium and magnesium excretion without significant changes in potassium and phosphate excretion, heart rate or blood pressure. 3. hANP caused a small change in fractional lithium clearance, and larger changes in distal nephron handling of sodium and water. 4. Plasma renin activity tended to decrease during the infusion of hANP, while plasma aldosterone concentration decreased during and increased after stopping the infusion of hANP. 5. The data suggest that hANP inhibits the reabsorption of sodium and water by an action on distal segments of the nephron and perhaps the proximal tubule. Inhibition of renin and aldosterone secretion may contribute to the natriuresis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2973849     DOI: 10.1042/cs0750403

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  4 in total

1.  Effects of atrial natriuretic peptide on systemic and renal hemodynamics and renal excretory function in patients with chronic renal failure.

Authors:  H Meyer-Lehnert; T Bayer; H G Predel; K Glänzer; H J Kramer
Journal:  Klin Wochenschr       Date:  1991-11-26

2.  Renal and hormonal effects and tolerance of an ANP analogue in healthy man.

Authors:  H Eiskjaer; M Schmiegelow; B Jespersen; I N Tietze; J D Jensen; S S Sørensen; K Thomsen; E B Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

4.  Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.

Authors:  Wei-Chi Liao; Ole Vesterqvist; Carol Delaney; Mohammed Jemal; Irene Ferreira; Neville Ford; Brian Swanson; Howard Uderman
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.